Hi Moreforme, I have no biotech background and appreciate the input of those who do. I hold PTX at the minute. We weathered a tough year in 2017 with clinical trials suspended for a period of time. All's on track again and I wouldn't at all be surprised if PTX out performs the market in 2018. Obviously DYO research for those not familiar with the Co/. But she's a beauty.
